CUE News and Press, Cue Biopharma Inc. From 02/22/23

BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today a col...

Collaboration with the laboratory of Dr. Michael Dustin elucidates the mechanism of action of Immuno-STATs in activating disease-specific T cells by mimicking the natural formation of immune synapses BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clin...

BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that ...

BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that ...

Cue Biopharma ( NASDAQ: CUE ) promotes its senior Vice President of clinical development, Matteo Levisetti, M.D., to Chief Medical Officer effective January 17, 2023. Current acting CMO Kenneth Pienta, M.D., has transitioned from his current role and will serve ...

Matteo Levisetti, M.D., promoted to Chief Medical Officer, effective January 17, 2023 Acting CMO Kenneth Pienta, M.D., to transition to a clinical advisory role BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical comp...

DALLAS, TX / ACCESSWIRE / November 17, 2022 / Public Ventures, LLC, a wholly owned subsidiary of MDB Capital Holdings, LLC , completed its first financing as a broker-dealer for Cue Biopharma, Inc. (NASDAQ:CUE). The Public Ventures' portion of the financing was completed via a private in...

Cue Biopharma, Inc. (CUE) Q3 2022 Earnings Conference Call November 14, 2022 16:30 ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Matteo Levisetti -...

Cue Biopharma press release ( NASDAQ: CUE ): Q3 GAAP EPS of -$0.31 beats by $0.07 . Revenue of $0.07M misses by $0.37M . For further details see: Cue Biopharma GAAP EPS of -$0.31 beats by $0.07, revenue of $0.07M misses by $0.37M

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, reported today th...